IngredientsD-ribose-L-cysteine (DRLC), also known as riboceine [2(R,S)-D-ribo-(1,2,3,4-tetrahydroxybutyl) thiazolidine-4(R)-carboxylic acid], is a synthetic analogue and a prodrug of cysteine that has been developed to support the intracellular synthesis of glutathione (GSH). The compound is also abbreviated in the scientific literature as RibCys. Its systematic IUPAC name is (4R)-2-[(1R,2R,3R)-1,2,3,4-tetrahydroxybutyl]-1,3-thiazolidine-4-carboxylic acid, with the CAS number 232617-15-1 and molecular formula C₈H₁₅NO₆S.
D-ribose-L-cysteine (riboceine) is a chemical compound developed as a cysteine prodrug intended to increase endogenous production of glutathione, a naturally occurring intracellular antioxidant. Structurally, it consists of D-ribose, a pentose sugar involved in cellular energy metabolism, chemically bound to L-cysteine, an amino acid required for glutathione biosynthesis.
RibCys is a thiazolidine prodrug of L-cysteine synthesized by the condensation of the sulfhydryl-containing amino acid with the aldose monosaccharide D-ribose. Both constituent molecules — D-ribose and L-cysteine — are naturally occurring biological substances. D-ribose is an endogenous pentose sugar fundamental to ATP and nucleic acid synthesis, while L-cysteine is a semi-essential sulfur-containing amino acid. The covalent condensation of these two naturally occurring molecules into a thiazolidine ring structure is a synthetic process; the product, D-ribose-L-cysteine, does not occur as such in nature.
D-ribose-L-cysteine, marketed as RiboCeine, is classified as a dietary supplement ingredient in the United States under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Manufacturers must submit a New Dietary Ingredient Notification (NDIN) to the FDA at least 75 days before marketing, as was done for D-Ribose-L-Cysteine by Max International, LLC in 2009, confirming its status for use in dietary supplements. Supplements containing RiboCeine are formulated in tablet or caplet (capsule-shaped tablet) form. U.S. patent 8,501,700 B2, issued in 2013, details methods to enhance glutathione and ATP levels in cells using such prodrugs, including RiboCeine compositions. These patents were assigned to entities such as Bioceuticals, Inc., and later licensed or transferred to Max International, providing that company with exclusive rights to formulate and commercialize D-ribose-L-cysteine in dietary supplements.
D-ribose-L-cysteine is a synthetic compound combining D-ribose (a naturally occurring sugar) and L-cysteine (an amino acid), both of which have individually been valued for their roles in energy metabolism and detoxification, respectively. There is no direct record of ribose-L-cysteine being used in ancient or traditional medicine in any cultural tradition. As a rationally designed synthetic prodrug, it has no historical ethnopharmacological use. Its individual component molecules — D-ribose and L-cysteine — have separate histories as recognized food and pharmaceutical constituents, but these are distinct from D-ribose-L-cysteine as an entity.
The scientific foundation for D-ribose-L-cysteine was laid by Roberts, Nagasawa, and colleagues, who investigated prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity, producing a family of 2-(polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids. The earliest peer-reviewed publications on the thiazolidine class, including RibCys, appear in the late 1980s and early 1990s in journals such as the Journal of Medicinal Chemistry and Toxicology Letters.
Thiazolidine prodrugs of cysteamine and L-cysteine were prepared by the condensation of each thioamine with the aldose monosaccharides, D-ribose and D-glucose, producing RibCyst, GlcCyst, RibCys, and GlcCys. The need for such protection arose from occupational exposure, nuclear accidents, environmental sources, and the protection of normal tissue during therapeutic irradiation of cancer. Sulfhydryl-containing compounds including cysteamine and L-cysteine had long been known to possess radioprotective properties, but their therapeutic utility is limited by their side effects at radioprotective doses. To avoid this drawback, these thiazolidine prodrugs were developed.
Traditional supplementation with L-cysteine or its precursor, N-acetylcysteine (NAC), has long been established for enhancing glutathione levels. D-ribose-L-cysteine was developed as a more stable and bioavailable alternative, aiming to release cysteine slowly for improved glutathione synthesis without the gastrointestinal discomfort sometimes associated with other forms.
D-ribose-L-cysteine (DRLC) is an analogue of cysteine that has been shown to boost cellular antioxidant capacity by enhancing intracellular biosynthesis of glutathione (GSH). The compound belongs to the thiazolidine-4-carboxylic acid class of prodrugs. The thiazolidine ring — a five-membered ring containing sulfur and nitrogen — is formed by the spontaneous condensation of the thiol and amine groups of L-cysteine with the aldehyde carbon of D-ribose. This ring formation masks the reactive thiol group of cysteine, protecting it from oxidation during gastrointestinal transit and systemic circulation.
Because cysteine itself can be neurotoxic when administered to mammals in high doses and degrades when ingested, RiboCeine delivers a bioavailable form of L-cysteine by releasing the sulfhydryl amino acid in vivo by non-enzymatic ring opening via hydrolysis. The liberated L-cysteine then stimulates hepatic glutathione biosynthesis. In addition to functioning as a prodrug for cysteine, the administration of RiboCeine delivers D-ribose to support adenosine triphosphate (ATP) synthesis.
The thiazolidine-4-(R)-carboxylic acid (TD) products of reactions of L-cysteine with carbonyl compounds serve as a "delivery" system for cysteine to the cell. Liberation of the amino acid can occur enzymatically as well as non-enzymatically. In the case of D-ribose-L-cysteine specifically, the released aldehyde co-product is D-ribose itself, which is non-toxic and metabolically useful, representing a design advantage over other thiazolidine prodrugs in which the aldehyde co-product could carry toxicity risk.
As oxidative stress increases the demand for cysteine in the cell for synthesis of glutathione, cysteine is gradually liberated from D-ribose-L-cysteine. The result is a more sustained level of glutathione compared with the more transient increases seen with direct cysteine supplementation. Glutathione (GSH) is a tripeptide (glutamate–cysteine–glycine) synthesized intracellularly; cysteine availability is the rate-limiting step in this biosynthesis. Glutathione is a tripeptide antioxidant molecule that contributes essentially to cellular homeostasis.
D-ribose-L-cysteine is a cysteine analogue designed to increase the synthesis of glutathione (GSH). GSH is a cofactor for glutathione peroxidase (GPx), the redox enzyme that catalyses the reduction of lipid peroxides. A low GPx activity and increased oxidised lipids are associated with the development of cardiovascular disease (CVD).
RibCys successfully elevated glutathione (GSH) levels in numerous organs of tumor-bearing CDF1 mice. GSH content was assayed 1, 2, 4, 8, and 16 hours after RibCys administration (8 mmol/kg, i.p.); various organs achieved maximal GSH content at different time points. GSH in the liver was elevated 1.5-fold compared to untreated controls at the 16-hour time point. Kidney GSH also was maximal at 16 hours and achieved 1.6-times control values. GSH in muscle achieved 2.5 times the levels in control animals, while the bladder was elevated 2.1-fold and the heart 1.8-fold. Other tissues tested (spleen, pancreas, lung) showed a 1.1- to 1.2-fold increase in GSH content. These preclinical findings established the compound's ability to raise tissue GSH broadly, not limited to a single organ.
DRLC (50 mg/kg and 100 mg/kg) reduced acetyl-cholinesterase activity and decreased NF-κB expression in the brains of LPS-treated mice. It also attenuated the cytoarchitectural distortions and loss of neuronal cells of the prefrontal cortex and hippocampus that were induced by LPS in mice. These results suggest that DRLC attenuates memory deficit induced by LPS through mechanisms related to the inhibition of oxidative stress, release of proinflammatory cytokines, and expression of NF-κB.
Note: The overwhelming majority of available evidence is derived from animal (rodent) and in vitro studies. As of the available literature, no large, randomized, double-blind, placebo-controlled human clinical trials for D-ribose-L-cysteine itself have been published in peer-reviewed form. Evidence strength is characterized accordingly for each area.
Evidence: Preclinical (animal); very limited human data
D-ribose-L-cysteine (RibCys) has been demonstrated to effectively promote the synthesis of glutathione, a potent neutralizer of reactive oxygen species (ROS). The foundational preclinical work by Roberts and Francetic (1991) in tumor-bearing CDF1 mice, cited above, showed dose-dependent, multi-organ GSH elevation. A 2014 study published in Atherosclerosis examined the compound in a transgenic mouse model: human lipoprotein(a) transgenic mice were treated with 4 mg/day ribose-cysteine (0.16 g/kg body weight) for 8 weeks. Ribose-cysteine increased GSH and GPx activity and lowered oxidised lipids, and significantly decreased LDL, apoB, and Lp(a) levels. The authors concluded that as ribose-cysteine lowers LDL, Lp(a), and oxidised lipid concentrations, it might be an ideal intervention to increase protection against the development of atherosclerosis. This study was in transgenic mice and cannot be directly extrapolated to humans.
Evidence: Preclinical (animal); historically in acetaminophen toxicity models
Protection against hepatotoxicity was among the earliest applications studied. Roberts, Nagasawa, and colleagues published on prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity, producing the 2-(polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids family in the Journal of Medicinal Chemistry (1987). A 1992 study specifically reported protection against acetaminophen hepatotoxicity by ribose-cysteine (RibCys) (Pharmacology & Toxicology, 70:281–285). A 2000 study (Slitt et al., Toxicologic Pathology) further reported that ribose-cysteine protects against acetaminophen-induced hepatic and renal toxicity.
More recently, a 2022 study published in Pathophysiology investigated the effect of D-ribose-L-cysteine (DRLC) in high-fructose high-fat (HFHF) diet-fed rats. Twenty rats (n=5 per group) were simultaneously exposed to HFHF and/or DRLC (250 mg/kg) orally during the 8 weeks of the study. Results showed that HFHF precipitated pro-inflammation and selective disruption of oxidative stress markers, including significant decreases in superoxide dismutase (SOD), glutathione peroxidase (GPX), and total antioxidant capacity (TAC). Significant increases in uric acid, TNF-α, CRP, and hepatic xanthine oxidase were observed in the HFHF group compared to controls. In the HFHF + DRLC group, oxidative stress was mitigated due to differences in serum levels of SOD, GPX, TAC, TNF-α, liver SOD, and XO relative to controls. All of this evidence is animal-based; no controlled human trials on hepatoprotective effects have been published.
Evidence: Preclinical (animal); no human trials
D-ribose-L-cysteine is an analogue of cysteine that has been shown to boost cellular antioxidant capacity by enhancing intracellular biosynthesis of glutathione (GSH). Deficiency of GSH has been implicated in the pathogenesis of Alzheimer's disease (AD). A 2020 study published in Drug Development Research evaluated DRLC on memory and scopolamine-induced amnesia in mice. Male Swiss mice were given oral administration of saline (10 ml/kg), DRLC (25, 50, and 100 mg/kg), or donepezil (1 mg/kg) 30 minutes before testing for memory performance using Y-maze and object recognition tasks. The study found dose-dependent improvements in memory performance and reductions in acetylcholinesterase activity and oxidative stress markers.
A 2020 study published in Naunyn-Schmiedeberg's Archives of Pharmacology investigated lipopolysaccharide (LPS)-induced neuroinflammation. The study evaluated the effects of DRLC on memory deficits and the biochemical and histo-morphological changes induced by LPS in mice. Male Swiss mice (n=10) were pre-treated orally with three doses of DRLC (25 mg/kg, 50 mg/kg, and 100 mg/kg), donepezil (1 mg/kg), or vehicle (saline) for 30 minutes prior to the intraperitoneal injection of LPS (0.25 mg/kg) daily for 7 days. Memory functions were evaluated using the Y-maze, object recognition, and social recognition tests. The specific brain regions (prefrontal cortex and hippocampus) were evaluated to determine oxidative stress biomarkers, acetylcholinesterase activity, proinflammatory cytokines (TNF-α and IL-6), expression of NF-κB, and neuronal cell morphology. DRLC (25–100 mg/kg) reversed the memory deficits in the LPS-treated mice (p<0.05). The increased oxidative stress and proinflammatory cytokines in the brain regions of the LPS-treated mice were significantly (p<0.05) reduced by DRLC.
A 2021/2022 study (published in Journal of Trace Elements in Medicine and Biology, PubMed 35617721) examined DRLC's effect on copper sulfate (CuSO₄)-induced memory deterioration, a model relevant to Alzheimer's disease pathology. The study evaluated the effect of D-ribose-L-cysteine (DRLC), a potent antioxidant agent, on copper sulfate (CuSO₄)-induced memory deterioration. Male Swiss mice were randomly distributed into 5 groups (n=10/group). Mice in group 1 were given distilled water (control), group 2 CuSO₄ (100 mg/kg), while groups 3–5 were pretreated with CuSO₄ (100 mg/kg) 30 minutes before administration of DRLC (10, 25, and 50 mg/kg). Treatments were given through oral gavage, daily for 28 days. The results suggest that D-ribose-L-cysteine enhances antioxidative defense system and reduced the release of inflammatory cytokines to mitigate hepatic injury and memory defect induced by copper sulfate in mice.
A study of paradoxical (REM) sleep deprivation in rats assessed anxiolytic and antioxidative effects. The study suggests that D-ribose-L-cysteine (DRLC) supplementation possibly attenuates and ameliorates behavioral deficits and neuronal damage of the hippocampus caused by paradoxical sleep deprivation via its anxiolytic and antioxidative properties.
A study on manganese-induced neurotoxicity (Neurotox Res, 2021) found that repeated manganese (Mn) exposure may cause increased production of reactive oxygen species (ROS), with a consequent imbalance in the glutathione (GSH) antioxidant defence system, resulting in cellular dysfunctions and eventually cell death, particularly in the brain. D-ribose-L-cysteine (RibCys) has been demonstrated to effectively promote the synthesis of glutathione, a potent neutralizer of ROS.
All neuroprotection studies to date are conducted in rodents. No human clinical trials examining cognitive or neuroprotective endpoints for DRLC have been identified in the peer-reviewed literature.
Evidence: Preclinical (animal only)
D-ribose-L-cysteine (DRLC), a potent glutathione (GSH) booster, has been recommended for relief of stress. Its adaptogenic-like effect was investigated in mice subjected to unpredictable chronic mild stress (UCMS). Adaptogens are substances that act nonspecifically to combat stress by regulating the key elements involved in stress-induced pathologies. The published study (PubMed 32959196, Naunyn-Schmiedeberg's Archives of Pharmacology, 2020) reported that DRLC exhibited adaptogenic-like activity in UCMS mice through inhibition of oxido-inflammatory responses and modulation of neuronal caspase-3 activity.
Evidence: Preclinical (animal); no human trials
GSH is a cofactor for glutathione peroxidase (GPx), the redox enzyme that catalyses the reduction of lipid peroxides. A low GPx activity and increased oxidised lipids are associated with the development of cardiovascular disease (CVD). As noted in the 2014 transgenic mouse study, ribose-cysteine increased hepatic and plasma GSH and GPx activity, lowered LDL, apoB, and Lp(a) levels, and reduced oxidised lipids — findings with potential implications for atherosclerosis risk, but demonstrated only in a transgenic animal model.
Evidence: Preclinical (animal only)
A 2018 study published in Toxicology Reports (PMC6104459) compared the antidiabetic effects of D-ribose-L-cysteine with insulin and oral hypoglycaemic agents in pregnant rats. The study aimed at comparing the antidiabetic effects of d-ribose-l-cysteine (riboceine) with vildagliptin, glibenclamide, metformin, glipizide and insulin in diabetes in pregnancy. Forty female Sprague-Dawley rats were mated with twenty male rats. Diabetes was induced by streptozotocin and the female rats were divided into 8 groups of five each. The animals were administered either of the OHAs vildagliptin, glibenclamide, metformin, glipizide and riboceine for a period of 19 gestational days. The decreased MDA levels and the concomitant increase in CAT and SOD antioxidants as seen in animals that received riboceine, vildagliptin, metformin and glipizide showed an abrogation of cellular redox.
A 2020 study in Comparative Clinical Pathology examined DRLC in streptozotocin-diabetic rats. Diabetes mellitus is a metabolic disease that causes oxidative imbalance resulting in an impairment of the steroidogenic function and reproductive dysfunctions. The study investigated the potency of D-ribose-L-cysteine in reversing hyperglycemia and reproductive histopathological alterations in streptozotocin-diabetic rats. Diabetes was induced in adult male Wistar rats with a single intraperitoneal injection of 70 mg/kg b.w. streptozotocin. The hyperglycemic rats were thereafter treated orally with D-ribose-L-cysteine (100 mg/kg b.w.) and metformin (30 mg/kg b.w.) respectively once daily for a period of 17 days.
Evidence: Preclinical (animal only)
Several rodent studies have examined DRLC's potential to mitigate toxicant-induced reproductive damage. One study examined the histomorphological response of D-ribose-L-cysteine to ketamine-induced testicular damage in adult male Wistar rats. Animals were randomly divided into four groups (n=5). Group A served as control receiving distilled water; group B received 50 mg/kg body weight of ketamine only; group C received 50 mg/kg of ketamine and 30 mg/kg of DRLC; group D received 30 mg/kg of DRLC only. Published studies have also examined DRLC against aluminum-induced testicular damage in Sprague-Dawley rats (Falana et al., JBRA Assisted Reproduction, 2017) and against sodium arsenate-induced testicular toxicity. A study evaluating D-ribose-L-cysteine against sodium arsenate-induced testicular toxicity used 32 male rats (150–250g) randomly divided into four groups (n=8). Group A received normal saline; Group B received 8 mg/kg BW of sodium arsenate only; Group C received sodium arsenate (8 mg/kg) and DRLC (10 mg/kg); Group D received sodium arsenate (8 mg/kg) and DRLC (30 mg/kg).
Evidence: Preclinical (animal; one rodent model study)
A study reported that D-ribose-L-cysteine supplementation enhances wound healing in a rodent model (American Journal of Surgery, 210, 153–158, 2015). No human wound-healing trials have been identified in the literature.
Evidence: Preclinical (animal); original research motivation for compound development
Radioprotection was among the earliest studied applications of this class of compounds. A study reported a "Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid," published in Diseases of the Colon and Rectum (1993), 36(7): 681–687. Additional studies on thiazolidine prodrugs as protective agents against γ-radiation-induced toxicity and mutagenesis were also conducted by Wilmore, Cassidy, Warters, and Roberts. All radioprotection data are from preclinical models.
The following dosages are reported only as stated in the cited sources and refer exclusively to preclinical animal study doses unless explicitly noted otherwise.
A New Dietary Ingredient Notification (NDIN) was submitted to the FDA by Max International, LLC in 2009. The FDA does not approve dietary supplements, including those containing D-ribose-L-cysteine, for specific therapeutic claims; products are sold for general wellness support, with manufacturers responsible for ensuring safety and accurate labeling under DSHEA regulations.
Cysteine itself is neurotoxic when administered to mammals, and is rapidly degraded. It was shown that N-acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate, as well as certain other thiazolidine derivatives can protect mice from hepatotoxic dosages of acetaminophen. The thiazolidine prodrug approach was explicitly adopted to avoid the neurotoxicity and instability of free cysteine. At the doses used in animal studies for DRLC specifically, neurotoxicity attributable to liberated free cysteine has not been prominently reported, though the limitation of very small study group sizes (typically n=5–10 per group) constrains conclusions.
Studies on prolonged administration reveal gaps in understanding chronic effects, with limited data available on potential toxicities or interactions in extended use scenarios. A 2024 review in ScienceDirect discussing the safety issues associated with d-ribose-L-cysteine acknowledges its potential in treating neurological damage, reproductive dysfunction, endocrine diseases, chondrocyte degeneration, and cardiometabolic syndrome, but also underscores the reliance on animal data. Scientific studies, including preclinical and limited human research, provide encouraging data regarding ribose-L-cysteine's efficacy and safety, but the body of human trial evidence remains very limited.
Upon hydrolysis, D-ribose-L-cysteine releases D-ribose. D-ribose has been noted in the clinical literature to potentially lower blood glucose levels. The antidiabetic action of DRLC is comparable to that of insulin and selected oral hypoglycaemic agents in pregnant rats, which raises a theoretical concern for blood-glucose lowering in individuals with diabetes or those receiving antidiabetic medications. This potential interaction has only been characterized in animal models.
No peer-reviewed human pharmacokinetic or pharmacodynamic interaction studies for D-ribose-L-cysteine with pharmaceutical drugs have been identified in the available literature. The compound's dual release of L-cysteine (a thiol amino acid participating in numerous cellular redox reactions) and D-ribose upon hydrolysis suggests theoretical caution in the context of medications that are sensitive to cellular redox state or blood glucose, but this has not been formally studied in human subjects.
In recent years, the emergence of d-ribose-L-cysteine as a potential treatment regimen for neuro-endocrinopathy, reproductive dysfunction, and cardiometabolic syndrome has been gaining attention. Reviewers discuss the safety issues associated with d-ribose-L-cysteine and its potential in treating neurological damage, reproductive dysfunction, endocrine diseases, chondrocyte degeneration, and cardiometabolic syndrome. However, the totality of the evidence base as of the available literature is characterized by: (1) preclinical (rodent) studies, predominantly from Nigerian, New Zealand, and South African academic institutions; (2) small sample sizes (typically n=5–10 animals per group); (3) a very limited number of human or clinical investigations; and (4) no registered randomized controlled trials (RCTs) in human subjects identified in the peer-reviewed literature specifically for D-ribose-L-cysteine as a distinct dietary ingredient. The preclinical mechanistic rationale is well-grounded in established GSH biochemistry, but clinical translation remains undemonstrated.
Health conditions that Ribose-l-cysteine may help support.
Ribose-L-cysteine (RibCys) is a bioavailable conjugate combining D-ribose (the ATP backbone) and cysteine (the rate-limiting glutathione precursor) to simultaneously provide ATP synthesis substrate and mitochondrial antioxidant protection, addressing two interconnected aspects of cellular energy support.
Body systems that Ribose-l-cysteine may help support.
Go back